

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Jacobson Pharma Corporation Limited**

**雅各臣科研製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code : 2633)**

### **POSITIVE PROFIT ALERT**

This announcement is made by Jacobson Pharma Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Director(s)**”) of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 September 2024 (the “**Interim Period**”) and the information currently available to the Board, the Group expects to record an increase of over 40% in the profit from continuing operations for the Interim Period as compared with the same period of last year.

The significant increase in profit for the period from continuing operations was primarily attributed to the solid performance in the generic drug business across both public and private sectors, complemented by revenue contributions from newly in-licensed products and the robust launch of new products. Increased operating leverage across our production facilities and financial savings derived from effective cost control measures also contributed to the growth.

As a result of the Company no longer consolidating the results of JBM (Healthcare) Limited (stock code: 2161) (“**JBM Healthcare**”) and its subsidiaries in the financial statements following the distribution of shares in JBM Healthcare as a special dividend in specie to the Shareholders, it is expected that there will be a slight decrease of no more than 9% on the profit attributable to equity shareholders of the Company for the Interim Period compared to the same period last year.

As at the date of this announcement, the consolidated results of the Group for the Interim Period have not yet been finalised. The information contained in this announcement is only based on a preliminary assessment by the Board with reference to unaudited consolidated management accounts of the Group for the Interim Period and the information currently available to the Board. Such information has not been reviewed and confirmed by the auditor of the Company, and may be subject to adjustments. Further details of the Group's performance will be disclosed in the interim results announcement of the Company for the Interim Period in accordance with the Listing Rules, which is expected to be published on 21 November 2024.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Jacobson Pharma Corporation Limited**  
**YU Chun Kau**  
*Company Secretary*

Hong Kong, 6 November 2024

*As at the date of this announcement, the Board comprises Mr. Sum Kwong Yip, Derek (also as Chairman and Chief Executive Officer), Mr. Yim Chun Leung and Ms. Pun Yue Wai as executive Directors, Professor Wong Chi Kei, Ian as non-executive Director, and Dr. Lam Kwing Tong, Alan, Mr. Young Chun Man, Kenneth and Professor Lam Sing Kwong, Simon as independent non-executive Directors.*